You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):注射用比阿培南通過仿製藥質量和療效一致性評價
格隆匯 04-26 18:11

格隆匯4月26日丨聯邦制藥(03933.HK)發佈公吿,公司全資附屬公司珠海聯邦制藥股份有限公司申報的注射用比阿培南(規格:0.3g)經國家藥品監督管理局審批,通過仿製藥質量和療效一致性評價。

根據披露,注射用比阿培南為新型碳青黴烯類抗生素,具有抗菌譜廣、對β-內醯胺酶穩定的特點。臨牀適用於由敏感細菌所引起的敗血症、肺炎、急性支氣管炎等的治療。相比於其它碳青黴烯類品種,比阿培南具有腎毒性小、無中樞神經系統毒性等特點。現時,比阿培南為國家醫保目錄(二零二一版)乙類藥品。

本次獲批將進一步有助於公司鞏固於抗感染領域的優勢地位。公司將持續致力於新產品研發及推進一致性評價,預期將為公司及其股東創造更大收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account